Screening for Impaired Glucose Homeostasis: A Novel Metric of Glycemic Control

筛查葡萄糖稳态受损:一种新的血糖控制指标

阅读:2

Abstract

OBJECTIVE: To investigate the use of a mathematical model of glucose homeostasis, fit to continuous glucose monitor data, as a metric of dysfunctional glycemic control. PATIENTS AND METHODS: Three hundred eighty four participants recruited from 2 studies between October 2020 and June 2022 were equipped with a continuous glucose monitor, and interstitial glucose data were automatically collected for 2 weeks. The participants were assessed by a physician and diagnosed as being diabetic, prediabetic, or healthy according to the American Diabetes Association guidelines. A mathematical model of glucose homeostasis was fitted to the glucose data, and model parameter values were obtained. The participants were classified into the following 2 groups on the basis of their glucose homeostasis parameters: effective and impaired. Finally, glycemic variability metrics were compared with glucose homeostasis classification. RESULTS: The homeostasis classification resulted in a specificity, sensitivity of individuals with prediabetes, and sensitivity of individuals with type 2 diabetes (T2D) of 0.78, 0.86, and 1.00, respectively, for women and 0.71, 0.86, and 1.00, respectively, for men. This sensitivity was similar to that of glycated hemoglobin A1c measurement (a sensitivity of 0.89 for women and 0.90 for men for prediabetes and a sensitivity of 1.00 for T2D) and superior to that of the oral glucose tolerance test (a sensitivity of 0.18 for women and 0.24 for men for prediabetes and a sensitivity of 0.75 for women and 0.86 for men for T2D). Overall, the individuals classified as impaired had increased glucose variability metrics than the individuals classified as effective (P<.05). CONCLUSION: The classification of glucose homeostasis on the basis of mathematical modeling of continuous measurements has promising applications as a new metric of dysfunctional glycemic control. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT04529239; clinical trial registry identifier: CTRI/2021/08/035957.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。